Asfar S Azmi

List of Publications by Year in Descending Order

142 papers	8,282 citations	44 h-index	89 g-index
166 ext. papers	9,527 ext. citations	7.2 avg, IF	6.12 L-index

#	Paper	IF	Citations
142	Connecting the Human Microbiome and Pancreatic Cancer.. *Cancer and Metastasis Reviews*, **2022**, 1	9.6	2
141	Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C-Mutant Cancers.. *Cancer Research Communications*, **2022**, 2, 342-352		1
140	Circular RNAs in acute myeloid leukemia. *Molecular Cancer*, **2021**, 20, 149	42.1	1
139	Potential of PAR-4 as a Therapeutic Target for Pancreatic Cancer **2021**, 161-170		
138	KRAS Inhibitors- yes but what next? Direct targeting of KRAS- vaccines, adoptive T cell therapy and beyond. *Cancer Treatment Reviews*, **2021**, 101, 102309	14.4	6
137	Updates and new directions in the use of radiation therapy for the treatment of pancreatic adenocarcinoma: dose, sensitization, and novel technology. *Cancer and Metastasis Reviews*, **2021**, 40, 879-889	9.6	0
136	Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase I Study. *Clinical Cancer Research*, **2021**, 27, 3307-3316	12.9	7
135	Gastrointestinal stromal tumor: a review of current and emerging therapies. *Cancer and Metastasis Reviews*, **2021**, 40, 625-641	9.6	6
134	microRNA-based diagnostic and therapeutic applications in cancer medicine. *Wiley Interdisciplinary Reviews RNA*, **2021**, 12, e1662	9.3	13
133	Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer. *Molecular Cancer*, **2021**, 20, 82	42.1	10
132	Exosomal microRNA in Pancreatic Cancer Diagnosis, Prognosis, and Treatment: From Bench to Bedside. *Cancers*, **2021**, 13,	6.6	8
131	PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus. *Molecular Cancer Therapeutics*, **2021**, 20, 1836-1845	6.1	1
130	The nuclear export protein XPO1 - from biology to targeted therapy. *Nature Reviews Clinical Oncology*, **2021**, 18, 152-169	19.4	32
129	Non-Coding RNAs in Pancreatic Cancer Diagnostics and Therapy: Focus on lncRNAs, circRNAs, and piRNAs. *Cancers*, **2021**, 13,	6.6	6
128	Targeting KRAS in pancreatic cancer: new drugs on the horizon. *Cancer and Metastasis Reviews*, **2021**, 40, 819-835	9.6	6
127	Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC). *Lung Cancer*, **2021**, 160, 92-98	5.9	2
126	Exportin 1 inhibition as antiviral therapy. *Drug Discovery Today*, **2020**, 25, 1775-1781	8.8	24

125	Natural agents inhibit colon cancer cell proliferation and alter microbial diversity in mice. *PLoS ONE*, **2020**, 15, e0229823	3.7	8
124	Calcium Release-Activated Calcium (CRAC) Channel Inhibition Suppresses Pancreatic Ductal Adenocarcinoma Cell Proliferation and Patient-Derived Tumor Growth. *Cancers*, **2020**, 12,	6.6	16
123	Prooxidant anticancer activity of plant-derived polyphenolic compounds: An underappreciated phenomenon **2020**, 221-236		5
122	KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?. *Cancer Treatment Reviews*, **2020**, 84, 101974	14.4	90
121	Gut microbiome and response to checkpoint inhibitors in non-small cell lung cancer-A review. *Critical Reviews in Oncology/Hematology*, **2020**, 145, 102841	7	14
120	Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma. *Clinical Cancer Research*, **2020**, 26, 1338-1348	12.9	18
119	Association of ALDH1A1-NEK-2 axis in cisplatin resistance in ovarian cancer cells. *Heliyon*, **2020**, 6, e05442	3.6	9
118	Restraint stress abates the antioxidant potential of melatonin on dimethyl benz (a) anthracene (DMBA) induced carcinogenesis. *Medical Oncology*, **2020**, 37, 96	3.7	3
117	Gastric cancer: a comprehensive review of current and future treatment strategies. *Cancer and Metastasis Reviews*, **2020**, 39, 1179-1203	9.6	61
116	Gastric Cancer Heterogeneity and Clinical Outcomes. *Technology in Cancer Research and Treatment*, **2020**, 19, 1533033820935477	2.7	7
115	Pre-clinical anti-tumor activity of BrutonS Tyrosine Kinase inhibitor in HodgkinS Lymphoma cellular and subcutaneous tumor model. *Heliyon*, **2019**, 5, e02290	3.6	2
114	Targeting Nuclear Exporter Protein XPO1/CRM1 in Gastric Cancer. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	13
113	Ras and exosome signaling. *Seminars in Cancer Biology*, **2019**, 54, 131-137	12.7	26
112	DNA-Methylation-Caused Downregulation of Contributes to the High Expression of XPO1 and the Aggressive Growth of Tumors in Pancreatic Ductal Adenocarcinoma. *Cancers*, **2019**, 11,	6.6	4
111	Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance. *International Journal of Molecular Sciences*, **2019**, 21,	6.3	7
110	PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors. *Cancers*, **2019**, 11,	6.6	13
109	miRNA and Gene Expression in Pancreatic Ductal Adenocarcinoma. *American Journal of Pathology*, **2019**, 189, 58-70	5.8	22
108	Pharmacotherapeutic strategies for treating pancreatic cancer: advances and challenges. *Expert Opinion on Pharmacotherapy*, **2019**, 20, 535-546	4	12

107	Targeting Rho GTPase effector p21 activated kinase 4 (PAK4) suppresses p-Bad-microRNA drug resistance axis leading to inhibition of pancreatic ductal adenocarcinoma proliferation. *Small GTPases*, **2019**, 10, 367-377	2.7	13
106	Paclitaxel and di-fluorinated curcumin loaded in albumin nanoparticles for targeted synergistic combination therapy of ovarian and cervical cancers. *Colloids and Surfaces B: Biointerfaces*, **2018**, 167, 8-19	6	56
105	Retraction notice to "Notch-1 induces Epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells". *Cancer Letters*, **2018**, 423, 153	9.9	0
104	The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities. *Expert Review of Anticancer Therapy*, **2018**, 18, 131-148	3.5	22
103	Nuclear Export Inhibition for Pancreatic Cancer Therapy. *Cancers*, **2018**, 10,	6.6	11
102	Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression. *Oncotarget*, **2018**, 9, 35327-35342	3.3	5
101	Rho GTPase effectors and NAD metabolism in cancer immune suppression. *Expert Opinion on Therapeutic Targets*, **2018**, 22, 9-17	6.4	9
100	Nuclear export mechanisms of circular RNAs: size does matter. *Non-coding RNA Investigation*, **2018**, 2,	0.6	4
99	Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma. *Molecular Cancer Therapeutics*, **2017**, 16, 76-87	6.1	49
98	Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration. *Oncotarget*, **2017**, 8, 82144-82155	3.3	32
97	Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer. *Oncotarget*, **2017**, 8, 44295-44311	3.3	20
96	F-BOX proteins in cancer cachexia and muscle wasting: Emerging regulators and therapeutic opportunities. *Seminars in Cancer Biology*, **2016**, 36, 95-104	12.7	19
95	Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-**B** deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death. *Oncotarget*, **2016**, 7, 78883-78895	3.3	65
94	The Role of microRNAs in the Diagnosis and Treatment of Pancreatic Adenocarcinoma. *Journal of Clinical Medicine*, **2016**, 5,	5.1	27
93	Targeting Cancer at the Nuclear Pore. *Journal of Clinical Oncology*, **2016**, 34, 4180-4182	2.2	11
92	Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone. *Cancer Letters*, **2016**, 383, 309-317	9.9	26
91	Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds. *Seminars in Cancer Biology*, **2015**, 35 Suppl, S55-S77	12.7	67
90	Broad targeting of resistance to apoptosis in cancer. *Seminars in Cancer Biology*, **2015**, 35 Suppl, S78-S103	12.7	368

89	Cancer prevention and therapy through the modulation of the tumor microenvironment. *Seminars in Cancer Biology*, **2015**, 35 Suppl, S199-S223	12.7	201
88	Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition. *Seminars in Cancer Biology*, **2015**, 35 Suppl, S5-S24	12.7	175
87	Sustained proliferation in cancer: Mechanisms and novel therapeutic targets. *Seminars in Cancer Biology*, **2015**, 35 Suppl, S25-S54	12.7	321
86	A multi-targeted approach to suppress tumor-promoting inflammation. *Seminars in Cancer Biology*, **2015**, 35 Suppl, S151-S184	12.7	76
85	Designing a broad-spectrum integrative approach for cancer prevention and treatment. *Seminars in Cancer Biology*, **2015**, 35 Suppl, S276-S304	12.7	179
84	Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition. *Scientific Reports*, **2015**, 5, 16077	4.9	22
83	Broad targeting of angiogenesis for cancer prevention and therapy. *Seminars in Cancer Biology*, **2015**, 35 Suppl, S224-S243	12.7	314
82	A novel small-molecule inhibitor of mcl-1 blocks pancreatic cancer growth in vitro and in vivo. *Molecular Cancer Therapeutics*, **2014**, 13, 565-75	6.1	145
81	The Biological Roles of MicroRNAs in Cancer Stem Cells **2014**, 295-320		
80	Rectifying cancer drug discovery through network pharmacology. *Future Medicinal Chemistry*, **2014**, 6, 529-39	4.1	15
79	Pancreatic cancer stem-like cells display aggressive behavior mediated via activation of FoxQ1. *Journal of Biological Chemistry*, **2014**, 289, 14520-33	5.4	42
78	Systems Biology of Pancreatic Cancer Stem Cells **2014**, 297-322		
77	Snail nuclear transport: the gateways regulating epithelial-to-mesenchymal transition?. *Seminars in Cancer Biology*, **2014**, 27, 39-45	12.7	55
76	Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer. *OncoTargets and Therapy*, **2014**, 7, 187-92	4.4	20
75	Differentially expressed miRNAs in cancer-stem-like cells: markers for tumor cell aggressiveness of pancreatic cancer. *Stem Cells and Development*, **2014**, 23, 1947-58	4.4	28
74	Systems and Network Pharmacology Strategies for Pancreatic Ductal Adenocarcinoma Therapy: A Resource Review **2014**, 405-425		
73	Prioritizing Diagnostic, Prognostic, and Therapeutic MicroRNAs in Pancreatic Cancer **2014**, 345-363		
72	Nuclear retention of Fbw7 by specific inhibitors of nuclear export leads to Notch1 degradation in pancreatic cancer. *Oncotarget*, **2014**, 5, 3444-54	3.3	41

71	Understanding XPO1 target networks using systems biology and mathematical modeling. *Current Pharmaceutical Design*, **2014**, 20, 56-65	3.3	11
70	Systems biology approaches to pancreatic cancer detection, prevention and treatment. *Current Pharmaceutical Design*, **2014**, 20, 73-80	3.3	7
69	Regulation of KRAS-PAK4 axis by microRNAs in cancer. *Current Pharmaceutical Design*, **2014**, 20, 5275-8	3.3	3
68	Targeting CSCs in tumor microenvironment: the potential role of ROS-associated miRNAs in tumor aggressiveness. *Current Stem Cell Research and Therapy*, **2014**, 9, 22-35	3.6	43
67	Metformin may function as anti-cancer agent via targeting cancer stem cells: the potential biological significance of tumor-associated miRNAs in breast and pancreatic cancers. *Annals of Translational Medicine*, **2014**, 2, 59	3.2	40
66	Systems Biology Approaches in the Design of Effective miRNA-Targeted Therapeutics **2014**, 327-337		
65	Systems analysis reveals a transcriptional reversal of the mesenchymal phenotype induced by SNAIL-inhibitor GN-25. *BMC Systems Biology*, **2013**, 7, 85	3.5	12
64	Activated K-Ras and INK4a/Arf deficiency promote aggressiveness of pancreatic cancer by induction of EMT consistent with cancer stem cell phenotype. *Journal of Cellular Physiology*, **2013**, 228, 556-562	7	39
63	Selective inhibitors of nuclear export block pancreatic cancer cell proliferation and reduce tumor growth in mice. *Gastroenterology*, **2013**, 144, 447-456	13.3	94
62	Attenuation of Multifocal Cell Survival Signaling by Bioactive Phytochemicals in the Prevention and Therapy of Cancer. *Evidence-based Anticancer Complementary and Alternative Medicine*, **2013**, 269-310		1
61	Systems and Network Biology to Investigate Epigenetic De-regulatory Mechanisms of MicroRNAs in Pancreatic Cancer **2013**, 1-12		
60	Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review. *Cancer and Metastasis Reviews*, **2013**, 32, 623-42	9.6	791
59	Overview of cancer stem cells (CSCs) and mechanisms of their regulation: implications for cancer therapy. *Current Protocols in Pharmacology*, **2013**, Chapter 14, Unit 14.25	4.1	148
58	Providing activation-induced cytidine deaminase (AID) to nuclear export inhibitors. Response to: "Complex downstream effects of nuclear export inhibition in B-cell lymphomas: a possible role for activation-induced cytidine deaminase". *Haematologica*, **2013**, 98, e123	6.6	
57	Selective inhibitors of nuclear export for the treatment of non-HodgkinS lymphomas. *Haematologica*, **2013**, 98, 1098-106	6.6	52
56	Unveiling the role of nuclear transport in epithelial-to-mesenchymal transition. *Current Cancer Drug Targets*, **2013**, 13, 906-14	2.8	19
55	Pro-oxidant activity of dietary chemopreventive agents: an under-appreciated anti-cancer property. *F1000Research*, **2013**, 2, 135	3.6	14
54	Nuclear export mediated regulation of microRNAs: potential target for drug intervention. *Current Drug Targets*, **2013**, 14, 1094-100	3	34

53	Adopting network pharmacology for cancer drug discovery. *Current Drug Discovery Technologies*, **2013**, 10, 95-105	1.5	20
52	Network insights into the genes regulated by hepatocyte nuclear factor 4 in response to drug induced perturbations: a review. *Current Drug Discovery Technologies*, **2013**, 10, 147-54	1.5	9
51	The Biology of the Deadly Love Connection Between Obesity, Diabetes, and Breast Cancer **2013**, 117-142		
50	The immunological contribution of NF-B within the tumor microenvironment: a potential protective role of zinc as an anti-tumor agent. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2012**, 1825, 160-72	11.2	16
49	The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2012**, 1826, 272-96	11.2	94
48	Resveratrol-induced apoptosis is enhanced in low pH environments associated with cancer. *Journal of Cellular Physiology*, **2012**, 227, 1493-500	7	51
47	Targeting CSCs within the tumor microenvironment for cancer therapy: a potential role of mesenchymal stem cells. *Expert Opinion on Therapeutic Targets*, **2012**, 16, 1041-54	6.4	33
46	Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. *Cancer Research*, **2012**, 72, 335-45	10.1	251
45	Network insights on oxaliplatin anti-cancer mechanisms. *Clinical and Translational Medicine*, **2012**, 1, 26	5.7	14
44	Hypoxia induced aggressiveness of prostate cancer cells is linked with deregulated expression of VEGF, IL-6 and miRNAs that are attenuated by CDF. *PLoS ONE*, **2012**, 7, e43726	3.7	99
43	Hypoxia-induced aggressiveness of pancreatic cancer cells is due to increased expression of VEGF, IL-6 and miR-21, which can be attenuated by CDF treatment. *PLoS ONE*, **2012**, 7, e50165	3.7	133
42	Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. *Cancer Prevention Research*, **2012**, 5, 355-64	3.2	273
41	Old wine in a new bottle: the Warburg effect and anticancer mechanisms of resveratrol. *Current Pharmaceutical Design*, **2012**, 18, 1645-54	3.3	38
40	Targeting CSC-related miRNAs for cancer therapy by natural agents. *Current Drug Targets*, **2012**, 13, 1858-68	3	42
39	Pan-Bcl-2 inhibitor AT-101 enhances tumor cell killing by EGFR targeted T cells. *PLoS ONE*, **2012**, 7, e47520	3.7	9
38	Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer. *PLoS ONE*, **2012**, 7, e52095	3.7	40
37	Systems and Network Pharmacology Approaches to Cancer Stem Cells Research and Therapy. *Journal of Stem Cell Research & Therapy*, **2012**, Suppl 7,	1	5
36	Prostate cancer stem cells: molecular characterization for targeted therapy. *Asian Journal of Andrology*, **2012**, 14, 659-60	2.8	5

35	Network Pharmacology: An Emerging Area in Anti-Cancer Drug Discovery **2012**, 393-418		
34	Progress in nanotechnology based approaches to enhance the potential of chemopreventive agents. *Cancers*, **2011**, 3, 428-45	6.6	42
33	Aberrant epigenetic grooming of miRNAs in pancreatic cancer: a systems biology perspective. *Epigenomics*, **2011**, 3, 747-59	4.4	17
32	Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. *Cancer Letters*, **2011**, 307, 26-36	9.9	261
31	Network perspectives on HDM2 inhibitor chemotherapy combinations. *Current Pharmaceutical Design*, **2011**, 17, 640-52	3.3	9
30	Restoring sensitivity to oxaliplatin by a novel approach in gemcitabine-resistant pancreatic cancer cells in vitro and in vivo. *International Journal of Cancer*, **2011**, 128, 1240-50	7.5	17
29	Down-regulation of Notch-1 is associated with Akt and FoxM1 in inducing cell growth inhibition and apoptosis in prostate cancer cells. *Journal of Cellular Biochemistry*, **2011**, 112, 78-88	4.7	74
28	Over-expression of FoxM1 leads to epithelial-mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells. *Journal of Cellular Biochemistry*, **2011**, 112, 2296-306	4.7	171
27	Emerging Bcl-2 inhibitors for the treatment of cancer. *Expert Opinion on Emerging Drugs*, **2011**, 16, 59-70	3.7	80
26	Pancreatic cancer: understanding and overcoming chemoresistance. *Nature Reviews Gastroenterology and Hepatology*, **2011**, 8, 27-33	24.2	257
25	Small molecule inhibitors of bcl-2 family proteins for pancreatic cancer therapy. *Cancers*, **2011**, 3, 1527-40	6.6	26
24	Activated K-ras and INK4a/Arf deficiency cooperate during the development of pancreatic cancer by activation of Notch and NF-B signaling pathways. *PLoS ONE*, **2011**, 6, e20537	3.7	35
23	Network modeling of MDM2 inhibitor-oxaliplatin combination reveals biological synergy in wt-p53 solid tumors. *Oncotarget*, **2011**, 2, 378-92	3.3	44
22	Network modeling of CDF treated pancreatic cancer cells reveals a novel c-myc-p73 dependent apoptotic mechanism. *American Journal of Translational Research (discontinued)*, **2011**, 3, 374-82	3	15
21	Targeting notch to eradicate pancreatic cancer stem cells for cancer therapy. *Anticancer Research*, **2011**, 31, 1105-13	2.3	58
20	Proof of concept: network and systems biology approaches aid in the discovery of potent anticancer drug combinations. *Molecular Cancer Therapeutics*, **2010**, 9, 3137-44	6.1	81
19	MDM2 inhibitors for pancreatic cancer therapy. *Mini-Reviews in Medicinal Chemistry*, **2010**, 10, 518-26	3.2	4
18	PAR-4 as a possible new target for pancreatic cancer therapy. *Expert Opinion on Therapeutic Targets* , **2010**, 14, 611-20	6.4	16

17	MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function. *European Journal of Cancer*, **2010**, 46, 1122-31	7.5	54
16	Review on molecular and therapeutic potential of thymoquinone in cancer. *Nutrition and Cancer*, **2010**, 62, 938-46	2.8	167
15	Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy. *Current Cancer Drug Targets*, **2010**, 10, 319-31	2.8	36
14	Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance. *Drug Resistance Updates*, **2010**, 13, 109-18	23.2	273
13	FoxM1 is a novel target of a natural agent in pancreatic cancer. *Pharmaceutical Research*, **2010**, 27, 1159-68	4.9	49
12	Structure-activity studies on therapeutic potential of Thymoquinone analogs in pancreatic cancer. *Pharmaceutical Research*, **2010**, 27, 1146-58	4.5	63
11	Emerging roles of PDGF-D signaling pathway in tumor development and progression. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2010**, 1806, 122-30	11.2	61
10	Targeting Notch signaling pathway to overcome drug resistance for cancer therapy. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2010**, 1806, 258-67	11.2	120
9	Plumbagin induces cell death through a copper-redox cycle mechanism in human cancer cells. *Mutagenesis*, **2009**, 24, 413-8	2.8	39
8	Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy. *Journal of Cellular Physiology*, **2009**, 218, 13-21	7	101
7	Cellular DNA breakage by soy isoflavone genistein and its methylated structural analogue biochanin A. *Molecular Nutrition and Food Research*, **2009**, 53, 1376-85	5.9	42
6	An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals. *Molecular Cancer*, **2009**, 8, 115	42.1	57
5	Evolving role of uPA/uPAR system in human cancers. *Cancer Treatment Reviews*, **2008**, 34, 122-36	14.4	334
4	Plant polyphenols mobilize nuclear copper in human peripheral lymphocytes leading to oxidatively generated DNA breakage: implications for an anticancer mechanism. *Free Radical Research*, **2008**, 42, 764-72	4	38
3	The anthocyanidin delphinidin mobilizes endogenous copper ions from human lymphocytes leading to oxidative degradation of cellular DNA. *Toxicology*, **2008**, 249, 19-25	4.4	30
2	Oxidative breakage of cellular DNA by plant polyphenols: a putative mechanism for anticancer properties. *Seminars in Cancer Biology*, **2007**, 17, 370-6	12.7	183
1	Prior exposure to restraint stress enhances 7,12-dimethylbenz(a)anthracene (DMBA) induced DNA damage in rats. *FEBS Letters*, **2006**, 580, 3995-9	3.8	20